sinc
first
isol
rhesu
macaqu
zika
forest
uganda
public
first
human
case
infect
zika
viru
zikv
mosquitoborn
envelop
rna
viru
becom
member
flaviviru
genu
flavivirida
famili
year
togeth
dengu
viru
denv
yellow
fever
viru
yfv
japanes
enceph
viru
jev
west
nile
viru
wnv
infect
zikv
arous
global
awar
recent
year
sever
neurolog
complic
syndrom
brasil
et
al
peixoto
et
al
congenit
zika
syndrom
baud
et
al
gurung
et
al
consist
mani
clinic
manifest
includ
intracrani
calcif
icc
cerebellar
hypoplasia
de
fatima
vasco
aragao
et
al
oliveira
melo
et
al
cui
et
al
remark
typifi
microcephali
found
human
anim
model
cui
et
al
although
symptom
major
infect
zikv
mild
asymptomat
addit
infect
zikv
lead
impair
human
spermatozoa
product
demonstr
decreas
sperm
count
earli
stage
zikv
infect
joguet
et
al
even
year
zikv
infect
abnorm
spermogram
result
could
still
observ
avelinosilva
et
al
sinc
local
outbreak
brazil
quick
spread
countri
effort
seek
inhibitor
suitabl
treatment
zikv
ongo
till
target
differ
stage
zikv
life
cycl
inhibitor
discov
wang
et
al
first
step
zikv
infect
attach
host
cell
membran
peptid
deriv
stem
region
e
protein
zikv
block
bind
virion
cell
via
interact
e
protein
disrupt
integr
viral
membran
yu
et
al
erythromycin
estol
also
found
effect
inhibit
zikv
infect
disrupt
integr
viral
membran
wang
et
al
curcumin
also
inhibit
infect
zikv
disturb
interact
virion
cell
delvecchio
et
al
fernando
et
al
li
et
al
mounc
et
al
nanchangmycin
one
antibiot
gramposit
bacteria
inhibit
zikv
infect
block
clathrinmedi
endocytosi
rausch
et
al
natur
oxysterol
also
inhibit
zikv
infect
probabl
owe
obstruct
membran
fusion
mediat
e
protein
li
et
al
inhibitor
interfer
viral
rna
replic
break
viral
life
cycl
exampl
adenosin
analog
inhibit
zikv
denv
replic
dosedepend
manner
vitro
termin
viral
rna
synthesi
protect
mice
zikv
infect
yin
et
al
deng
et
al
emricasan
pancaspas
inhibitor
held
back
increas
activ
induc
zikv
infect
protect
neural
progenitor
xu
et
al
screen
food
drug
administr
fda
approv
pregnanc
categori
b
drug
identifi
montelukast
antiasthmat
drug
antivir
activ
montelukast
zikv
two
flavivirus
denv
yfv
vitro
evalu
montelukast
also
exhibit
protect
efficaci
zikv
vertic
transmiss
lethal
challeng
underli
mechan
infect
inhibit
flavivirus
caus
montelukast
investig
well
studi
cell
babi
hamster
kidney
cell
vero
cell
african
green
monkey
kidney
cell
rd
cell
rhabdomyosarcoma
cell
human
astrocytoma
cell
line
mg
cultur
dulbecco
modifi
eagl
medium
dmem
biolog
industri
israel
supplement
fetal
bovin
serum
fb
biolog
industri
israel
mosquito
cell
grown
dmem
contain
fb
zikv
strain
genbank
number
isol
patient
return
samoa
kindli
provid
dr
chengfeng
qin
deng
et
al
zikv
strain
flr
american
type
cultur
collect
atcc
atcc
obtain
atcc
kindli
provid
dr
yunwen
hu
zhigang
song
shanghai
public
health
clinic
center
yfv
strain
obtain
beij
tiantan
biolog
product
ltd
propag
cell
describ
previous
yu
et
al
replicationcompet
vesicular
stomat
viru
vsv
contain
addit
viral
transcript
unit
code
green
fluoresc
protein
vsvgfp
kindli
provid
dr
nannan
wu
wu
et
al
propag
vero
cell
enteroviru
kindli
provid
dr
shuy
zhang
yuan
et
al
propag
rd
cell
montelukast
sodium
chloroquin
phosphat
purchas
sigmaaldrich
st
loui
mo
unit
state
curcumin
purchas
medchemexpress
monmouth
junction
nj
unit
state
montelukast
mon
curcumin
dissolv
dimethyl
sulfoxid
dmso
chloroquin
phosphat
dissolv
steril
water
dissolv
compound
store
plaqu
assay
perform
cell
vero
cell
previous
describ
yu
et
al
briefli
vero
cell
seed
onto
cell
cultur
plate
incub
overnight
confluent
monolay
viru
mixtur
viru
compound
ad
well
incub
h
supernat
remov
well
wash
cover
overlay
dmem
contain
lowmeltingpoint
agaros
lmp
agaros
promega
unit
state
fb
plate
incub
approxim
day
plaqu
develop
vsvgfp
plate
incub
day
plaqu
develop
fix
formaldehyd
stain
crystal
violet
plaqu
visual
plaqueform
unit
pfu
count
cell
vero
cell
seed
sixwel
plate
allow
adher
overnight
montelukast
sodium
serial
dilut
serumfre
dmem
pfu
virus
mix
incub
h
room
temperatur
ad
well
cell
incub
h
plaqu
assay
perform
plaqu
visual
describ
curcumin
report
antivir
drug
mounc
et
al
includ
posit
control
percent
inhibit
montelukast
calcul
inhibitori
concentr
valu
determin
use
softwar
calcusyn
chou
talalay
mg
cell
infect
zikv
strain
multipl
infect
moi
virus
incub
serial
dilut
montelukast
h
inoculum
remov
h
later
fresh
dmem
contain
fb
serial
dilut
montelukast
supplement
cell
trypsin
fix
permeabil
bd
fixationpermeabil
kit
bd
bioscienc
unit
state
h
postinfect
hpi
stain
anti
mab
rabbit
antimous
igg
coupl
fluorescein
isothiocyan
fitc
dako
denmark
dilut
flow
cytometri
experi
carri
lsrfortessa
cell
analyz
bd
bioscienc
sampl
analyz
use
flowjo
softwar
version
treestar
vero
mg
cell
grown
plate
cellswel
treat
serial
dilut
montelukast
dmem
contain
fb
h
cell
count
dojindo
japan
watersolubl
nonradioact
reagent
allow
sensit
colorimetr
assay
determin
cell
viabil
use
evalu
cytotox
accord
instruct
manual
absorb
wavelength
measur
imarktm
micropl
reader
biorad
unit
state
percent
cytotox
calcul
cytotox
concentr
valu
determin
calcusyn
chou
talalay
determin
stage
montelukast
display
inhibitori
effici
time
addit
assay
perform
previous
describ
du
et
al
liu
et
al
cell
confluent
sixwel
cell
cultur
plate
infect
pfu
viru
montelukast
ad
infect
cell
hpi
supernat
replac
dmem
contain
lmp
agaros
fb
hpi
plaqu
assay
perform
plaqu
visual
count
describ
test
whether
montelukast
inhibit
viru
attach
assay
viru
adsorpt
perform
previous
describ
talarico
et
al
cell
confluent
sixwel
plate
infect
pfu
viru
presenc
absenc
montelukast
incub
h
ice
curcumin
show
antivir
activ
stage
viru
adsorpt
mounc
et
al
includ
control
supernat
contain
unadsorb
viru
discard
cell
wash
twice
icecold
dmem
dmem
contain
lmp
agaros
fb
overlaid
viru
plaqu
visual
count
describ
viru
intern
assay
perform
previous
describ
talarico
et
al
si
et
al
cell
confluent
sixwel
plate
infect
pfu
virus
ice
h
viru
adsorpt
unadsorb
viru
discard
cell
wash
icecold
dmem
transfer
presenc
absenc
montelukast
chloroquin
phosphat
show
antivir
activ
stage
viru
intern
delvecchio
et
al
li
et
al
includ
control
h
incub
cell
wash
dmem
cover
dmem
contain
lmp
agaros
fb
viru
plaqu
visual
count
describ
test
whether
montelukast
inhibit
viral
rna
replic
assay
perform
hpi
time
entri
occur
rausch
et
al
briefli
cell
confluent
sixwel
plate
infect
pfu
viru
h
incub
supernat
remov
replac
dmem
presenc
absenc
montelukast
show
antivir
activ
stage
viru
rna
replic
deng
et
al
includ
control
incub
addit
h
supernat
remov
cell
wash
dmem
overlaid
dmem
contain
lmp
agaros
fb
viru
plaqu
visual
count
describ
test
whether
inhibit
montelukast
flaviviru
infect
revers
infect
inhibit
revers
assay
perform
previous
describ
modif
lok
et
al
viru
measur
pfu
incub
montelukast
total
volum
dmem
h
room
temperatur
immedi
ad
cell
monolay
virusmontelukast
mixtur
dilut
dmem
ml
reduc
concentr
montelukast
viru
constantli
treat
montelukast
includ
control
plaqu
assay
perform
viru
plaqu
visual
count
describ
detect
whether
montelukast
releas
genom
rna
flaviviru
particl
rnase
digest
assay
quantit
revers
transcript
qrt
pcr
perform
previous
describ
lok
et
al
yu
et
al
briefli
montelukast
differ
concentr
incub
zikv
pfu
h
rna
releas
viru
digest
micrococc
nucleas
new
england
biolab
rowley
unit
state
h
viral
genom
rna
insid
unbroken
viru
extract
use
easypur
viral
dnarna
kit
transgen
biotech
beij
china
detect
qrtpcr
use
transscript
green
onestep
qrtpcr
supermix
transgen
biotech
beij
china
realtim
system
biorad
unit
state
accord
manufactur
instruct
virion
zikv
yfv
also
purifi
rnase
digest
assay
polyethylen
glycol
peg
precipit
describ
previous
yu
et
al
briefli
amresco
unit
state
nacl
ad
viru
final
concentr
respect
incub
ice
overnight
mixtur
centrifug
g
h
supernat
discard
pellet
contain
virion
wash
pb
contain
mgml
bovin
serum
albumin
bsa
amresco
unit
state
centrifug
pellet
resuspend
pb
rnase
digest
assay
perform
unenvelop
rna
viru
includ
neg
control
primer
use
detect
rna
sequenc
zikv
yfv
describ
previous
lok
et
al
fernandesmonteiro
et
al
fischer
et
al
yu
et
al
wu
et
al
yuan
et
al
list
tabl
anim
experi
carri
accord
ethic
guidelin
approv
shanghai
public
health
clinic
center
laboratori
anim
welfar
ethic
committe
antivir
efficaci
montelukast
pregnant
mice
determin
previous
describ
wu
et
al
yu
et
al
briefli
pregnant
mice
randomli
assign
two
group
infect
intraperiton
ip
pfu
zikv
one
hour
later
infect
mice
ip
administ
montelukast
dissolv
pb
mgkg
bodi
weight
n
pb
vehicl
control
n
mice
bled
retroorbit
measur
viremia
qrtpcr
day
postinfect
two
embryo
collect
randomli
pregnant
mous
viral
rna
load
fetal
head
collect
embryo
placenta
determin
qrtpcr
evalu
antivir
efficaci
montelukast
vivo
mice
use
previous
describ
yin
et
al
deng
et
al
et
al
yu
et
al
tai
et
al
briefli
mice
randomli
assign
two
group
infect
ip
zikv
strain
dose
pfu
mous
one
hour
later
infect
mice
ip
administ
montelukast
dissolv
pb
mgkg
bodi
weight
n
pb
vehicl
control
n
treatment
perform
day
six
consecut
day
follow
daili
observ
mortal
mice
deem
protect
mous
surviv
day
postinfect
dpi
viral
rna
load
sera
dpi
measur
qrtpcr
statist
analys
carri
use
graphpad
prism
graphpad
softwar
inc
statist
method
list
follow
logrank
test
evalu
differ
surviv
nonparametr
test
examin
differ
viral
rna
load
sera
fetal
placenta
fetal
head
student
unpair
twotail
ttest
case
signific
differ
defin
p
p
identifi
drug
could
inhibit
infect
zikv
fdaapprov
drug
repurpos
screen
perform
cell
infect
mixtur
zikv
strain
drug
final
concentr
zikvinduc
cytopath
effect
cpe
cell
obviou
highli
watersolubl
nonradioact
reagent
like
xtt
allow
sensit
colorimetr
assay
determin
cell
viabil
use
detect
antivir
activ
drug
montelukast
show
inhibit
zikv
infect
select
studi
confirm
antivir
activ
montelukast
whose
chemic
structur
shown
figur
zikv
infect
plaqu
reduct
assay
employ
two
differ
cell
type
vero
first
test
antivir
efficaci
montelukast
infect
zikv
strain
show
montelukast
inhibit
zikv
strain
infect
dosedepend
manner
similar
valu
cell
figur
tabl
vero
cell
figur
tabl
known
zikv
classifi
two
distinct
phylogenet
lineag
african
asian
lineag
intrins
differ
pathogen
virul
two
lineag
zikv
simonin
et
al
test
montelukast
could
block
infect
differ
zikv
strain
asian
african
lineag
shown
figur
besid
zikv
strain
asian
lineag
montelukast
also
potent
inhibit
infect
zikv
strain
african
lineag
flr
asian
lineag
valu
cell
figur
tabl
vero
cell
figur
g
tabl
respect
indic
montelukast
effect
block
infect
two
lineag
zikv
strain
isol
rhesu
monkey
patient
diverg
region
furthermor
antivir
activ
montelukast
zikv
strain
infect
human
astrocytoma
cell
mg
test
show
montelukast
also
effect
inhibit
infect
zikv
mg
cell
valu
tabl
supplementari
figur
cytotox
montelukast
cell
vero
cell
mg
cell
evalu
use
exclud
possibl
cytotoxicityinduc
viral
reduct
figur
tabl
follow
interest
whether
montelukast
could
inhibit
infect
denv
yfv
two
import
mosquitoborn
flavivirus
circul
around
world
found
montelukast
could
also
effect
block
infect
yfv
valu
cell
vero
cell
respect
figur
b
tabl
result
suggest
montelukast
may
possess
broad
antivir
activ
infect
wide
spectrum
flavivirus
montelukast
leukotrien
receptor
antagonist
success
develop
treatment
asthmat
patient
bakhireva
et
al
caverocarbonel
et
al
howev
littl
known
potenti
mechan
antivir
activ
zikv
denv
yfv
order
determin
stage
viral
life
cycl
montelukast
execut
antivir
function
first
investig
influenc
time
addit
plaqu
format
cell
montelukast
ad
viru
simultan
time
differ
time
point
viral
infect
hpi
supernat
discard
cell
wash
perform
plaqu
assay
evalu
inhibitori
effect
montelukast
differ
time
point
shown
figur
simultan
addit
montelukast
zikv
cell
time
maxim
decreas
plaqu
number
time
laps
h
inhibitori
activ
montelukast
gradual
decreas
inhibitori
effect
plaqu
format
bare
observ
montelukast
ad
hpi
indic
montelukast
hardli
suppress
flaviviru
rna
replic
late
stage
confirm
assay
viral
rna
replic
figur
montelukast
adenosin
nucleosid
inhibitor
target
stage
flaviviru
rna
replic
yin
et
al
deng
et
al
ad
hpi
pattern
time
addit
experi
assay
viral
rna
replic
similar
figur
e
yfv
figur
f
suggest
montelukast
inhibit
flaviviru
infect
earli
stage
earli
stage
viru
infect
consist
process
includ
viral
attach
intern
effect
montelukast
viru
adsorpt
intern
evalu
separ
previous
describ
talarico
et
al
talarico
damont
ascertain
particular
inhibitori
step
earli
stage
zikv
life
cycl
cell
incub
simultan
zikv
montelukast
ice
lowtemperatur
condit
viru
attach
cell
event
viru
life
cycl
occur
talarico
et
al
shown
figur
montelukast
block
zikv
attach
amount
cellbound
viru
particl
highli
decreas
presenc
montelukast
compar
extent
caus
curcumin
known
inhibitor
suppress
zikv
attach
cell
mounc
et
al
inhibitori
effect
montelukast
subsequ
step
viru
intern
next
analyz
viru
adsorpt
ice
unbound
viru
remov
montelukast
subsequ
ad
cell
cultur
temperatur
immedi
shift
initi
viru
penetr
plaqu
assay
perform
thereaft
chloroquin
phosphat
known
inhibitor
block
viru
intern
includ
control
show
montelukast
littl
effect
intern
zikv
figur
pattern
effect
montelukast
adsorpt
intern
figur
e
yfv
figur
f
similar
zikv
overal
result
indic
antivir
action
montelukast
mainli
took
place
adsorpt
step
earli
stage
viru
life
cycl
next
montelukast
obstruct
flaviviru
infect
adsorpt
step
becam
natur
question
whether
inhibit
action
revers
infect
inhibit
revers
assay
employ
clarif
zikv
first
treat
montelukast
concentr
suffici
produc
approxim
inhibit
infect
mixtur
viru
montelukast
dilut
concentr
expect
produc
neglig
inhibit
immedi
plaqu
assay
perform
zikv
constantli
treat
constantli
treat
montelukast
also
includ
plaqu
assay
shown
figur
dilut
montelukast
could
abolish
inhibitori
effect
indic
inhibit
zikv
infect
irrevers
similarli
revers
inhibit
observ
figur
yfv
figur
irrevers
inhibitori
effect
montelukast
arous
interest
whether
releas
viral
genom
rna
induc
montelukast
potenti
viral
rna
releas
measur
rnase
digest
assay
describ
previous
lok
et
al
yu
et
al
rna
genom
intact
virion
would
protect
rnase
digest
wherea
virion
whose
integr
disrupt
treatment
would
suscept
rna
degrad
rnase
digest
shown
figur
viral
genom
rna
zikv
treat
montelukast
digest
micrococc
nucleas
dosedepend
manner
almost
genom
rna
zikv
particl
treat
montelukast
digest
montelukast
treatment
caus
similar
rna
genom
degrad
upon
rnase
digest
figur
yfv
figur
purifi
virion
zikv
yfv
figur
suggest
montelukast
could
disrupt
integr
flavivirus
henc
irrevers
destroy
infect
flavivirus
evalu
whether
montelukast
could
block
vertic
transmiss
zikv
pregnant
mice
infect
zikv
describ
previous
wu
et
al
yu
et
al
treat
montelukast
vehicl
control
shown
figur
treatment
montelukast
could
reduc
viremia
pregnant
mice
infect
zikv
p
meanwhil
viral
rna
load
placenta
pregnant
mice
treat
montelukast
greatli
reduc
compar
vehicletr
mice
p
infect
rate
declin
figur
montelukast
treatment
led
signific
decreas
viral
rna
load
fetal
head
p
figur
infect
rate
result
suggest
montelukast
may
lower
infect
rate
fetus
inactiv
zikv
virion
either
viru
invad
placenta
fetu
henc
protect
vertic
transmiss
zikv
pregnant
mice
like
peptidebas
viral
inactiv
yu
et
al
final
antivir
efficaci
montelukast
zikv
infect
evalu
recent
establish
interferon
alphabeta
receptordefici
dai
et
al
et
al
yu
et
al
tai
et
al
mous
model
mice
challeng
zikv
ip
subsequ
treat
montelukast
vehicl
mice
treat
vehicl
exhibit
mortal
rate
dpi
shown
figur
instead
mice
treat
montelukast
protect
death
caus
zikv
infect
p
logrank
test
viral
load
mice
treat
montelukast
dpi
much
lower
mice
treat
vehicl
p
figur
although
montelukast
suppress
zikv
infect
earli
stage
viral
life
cycl
consecut
inject
zikv
invad
cell
could
still
render
protect
possibl
irrevers
disrupt
newli
produc
virus
henc
prevent
infect
target
cell
zikv
one
mosquitoborn
flavivirus
discov
year
ago
spread
world
recent
year
caus
syndrom
congenit
zika
syndrom
damag
testicular
tissu
brasil
et
al
baud
et
al
gurung
et
al
peixoto
et
al
current
vaccin
drug
approv
prevent
treatment
zikv
infect
lead
necess
urgenc
develop
antizikv
therapi
repurpos
screen
clinic
approv
drug
practic
way
deal
outbreak
emerg
reemerg
infecti
diseas
threat
middl
east
respiratori
syndrom
mer
ebola
johansen
et
al
de
wild
et
al
dyall
et
al
kouznetsova
et
al
wang
et
al
employ
method
drug
found
effect
zikv
infect
xu
et
al
also
identifi
market
antiasthmat
drug
montelukast
report
far
know
montelukast
one
leukotrien
receptor
antagonist
prescrib
cysteinyl
leukotrien
antagonist
safe
use
asthmat
patient
mani
year
hoxha
et
al
interest
montelukast
exhibit
potenti
antivir
efficaci
zikv
vitro
vivo
montelukast
inhibit
infect
sever
type
flavivirus
includ
zikv
asian
african
lineag
yfv
two
kind
cell
also
protect
mice
lethal
zikv
challeng
block
vertic
transmiss
zikv
pregnant
mice
inhibit
zikv
infect
montelukast
irrevers
probabl
owe
disrupt
integr
zikv
virion
releas
zikv
genom
rna
note
concentr
need
caus
degrad
genom
littl
bit
higher
concentr
requir
yield
reduct
infect
also
report
studi
other
lok
et
al
yu
et
al
mention
studi
might
caus
use
virus
genom
degrad
assay
virion
partial
genom
releas
still
protect
degrad
like
noninfecti
interestingli
montelukast
effect
genom
rna
releas
unenvelop
rna
viru
supplementari
figur
supplementari
figur
show
amplicon
zikv
yfv
resolv
agaros
gel
electrophoresi
besid
montelukast
also
exhibit
antivir
activ
vsvgfp
supplementari
figur
envelop
nonflaviviru
suggest
montelukast
probabl
target
lipid
membran
viral
shell
envelop
protein
viru
hand
proven
pharmacolog
action
montelukast
could
favor
antivir
effect
concomit
effect
leukotrien
import
mediat
vascular
leakag
caus
denv
infectioninduc
mast
cell
activ
lead
increas
vascular
permeabl
may
result
hemorrhag
within
intern
organ
leakag
plasma
tissu
distinct
featur
dengu
shock
syndrom
dss
dengu
hemorrhag
fever
dhf
ahmad
et
al
montelukast
leukotrien
receptor
antagonist
could
reduc
vascular
permeabl
restor
vascular
integr
prevent
vascular
leakag
hemorrhag
st
john
st
john
et
al
henc
possibl
modul
inflamm
montelukast
would
contribut
vivo
antizikv
effect
certainli
put
mechan
underli
antivir
action
montelukast
blockag
bind
zikv
e
protein
cell
receptor
total
exclud
howev
receptor
util
zikv
still
controversi
govero
et
al
nowakowski
et
al
retallack
et
al
chen
et
al
therefor
investig
need
follow
research
major
sequela
caus
congenit
zikv
infect
microcephali
evidenc
human
anim
model
tang
et
al
cui
et
al
pregnant
women
direct
victim
zikv
infect
fetu
make
vital
import
treatment
pregnant
women
infect
zikv
cautiou
luckili
montelukast
classifi
categori
b
fda
pregnanc
categori
success
use
treatment
pregnant
women
asthma
bakhireva
et
al
caverocarbonel
et
al
anim
studi
show
advers
effect
embryo
fetal
develop
oral
dose
mgkgday
rat
mgkgday
rabbit
describ
product
inform
montelukast
trade
name
produc
merck
sharp
dohm
ltd
combin
fact
montelukast
block
vertic
transmiss
zikv
pregnant
mice
safeti
profil
pregnant
women
promis
montelukast
could
use
treatment
pregnant
women
infect
zikv
surpris
excit
us
montelukast
display
neuroprotect
activ
sever
anim
model
montelukast
may
improv
fiber
connect
longterm
function
recoveri
brain
ischemia
caus
stroke
enhanc
recruit
matur
oligodendrocyt
precursor
cell
gelosa
et
al
may
amelior
memori
impair
via
inhibit
neuroinflamm
apoptosi
mice
lai
et
al
moreov
treatment
old
anim
montelukast
reduc
neuroinflamm
elev
hippocamp
neurogenesi
improv
learn
memori
marschalling
et
al
montelukastmedi
restor
cognit
function
correl
increas
neurogenesi
consider
role
neuroinflamm
play
occurr
develop
microcephali
induc
zikv
infect
hope
montelukast
may
use
relief
neuroinflamm
taken
togeth
montelukast
exhibit
potent
antivir
efficaci
sever
flavivirus
includ
zikv
asian
african
lineag
yfv
via
irrevers
inhibit
infect
caus
disrupt
integr
virion
confer
protect
lethal
zikv
challeng
block
vertic
transmiss
zikv
indic
potenti
applic
treatment
zikv
infect
especi
highrisk
popul
pregnant
women
consid
safeti
profil
neuroprotect
activ
dataset
generatedfor
studi
includ
articlesupplementari
materi
anim
studywa
review
approv
shanghai
public
health
clinic
center
laboratori
anim
welfar
ethic
committe
pz
conceiv
design
experi
yc
yl
xw
perform
experi
yc
yl
analyz
data
yc
yl
pz
wrote
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
review
cfq
declar
past
coauthorship
one
author
pz
handl
editor
